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Abstract. 
 
Zellweger syndrome and related diseases are 
caused by defective import of peroxisomal matrix pro-
teins. In all previously reported Zellweger syndrome 
cell lines the defect could be assigned to the matrix pro-
tein import pathway since peroxisome membranes 
were present, and import of integral peroxisomal mem-
brane proteins was normal. However, we report here a 
Zellweger syndrome patient (PBD061) with an unusual 
cellular phenotype, an inability to import peroxisomal 
membrane proteins. We also identified human PEX16, 
a novel integral peroxisomal membrane protein, and 
found that PBD061 had inactivating mutations in the 
 
PEX16
 
 gene. Previous studies have suggested that per-
oxisomes arise from preexisting peroxisomes but we 
find that expression of 
 
PEX16
 
 restores the formation of 
new peroxisomes in PBD061 cells. Peroxisome synthe-
sis and peroxisomal membrane protein import could be 
detected within 2Ð3 h of 
 
PEX16
 
 injection and was fol-
lowed by matrix protein import. These results demon-
strate that peroxisomes do not necessarily arise from 
division of preexisting peroxisomes. We propose that 
peroxisomes may form by either of two pathways: one 
that involves PEX11-mediated division of preexisting 
peroxisomes, and another that involves PEX16-medi-
ated formation of peroxisomes in the absence of preex-
isting peroxisomes.
Key words: membrane biogenesis ¥ Zellweger syn-
drome ¥ peroxisomal membrane protein import ¥ 
PEX16 ¥ peroxisome biogenesis disorders
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1.
 
 Abbreviations used in this paper:
 
 DPBS, DulbeccoÕs phosphate-buffered
saline; PBD, peroxisome biogenesis disorders; PMP, peroxisomal mem-
brane protein.
 
M
 
EMBRANE
 
-
 
BOUND
 
 organelles appear to be synthe-
sized by fission and fusion of homotypic organelles
or budding from heterotypic organelles. These
common modes of organelle biogenesis also represent at-
tractive models for peroxisome biogenesis. The hypothesis
that peroxisomes are derived from the ER was proposed
nearly 30 yr ago (Novikoff and Shin, 1964). However, this
hypothesis was largely abandoned when it was found that
peroxisomal enzymes were imported directly from the cyto-
plasm to the peroxisome, rather than via the ER (Lazarow
et al., 1982). Peroxisomal membrane proteins (PMPs)
 
1
 
 are
also imported directly from the cytoplasm (Fujiki et al.,
1984), and together these results led to the currently fa-
vored hypothesis that peroxisomes form by division of
preexisting peroxisomes (Lazarow and Fujiki, 1985). How-
ever, there is little direct evidence for how peroxisomes
are synthesized.
To distinguish between these different models for per-
oxisome biogenesis we and others have searched for mu-
tants that are unable to import PMPs into peroxisomes,
and thus, fail to synthesize peroxisome membranes. In ad-
dition to studies in yeast (Hhfeld et al., 1991; Wiemer et al.,
1996; Gotte et al., 1998) (Gould, S.J., and S. South, manu-
script in preparation), we have examined human cell lines
derived from patients who suffer from disorders of peroxi-
some biogenesis. The peroxisome biogenesis disorders
(PBDs) include Zellweger syndrome, neonatal adrenoleu-
kodystrophy, infantile Refsum disease, and rhizomelic
chondrodysplasia punctata (Lazarow and Moser, 1995).
This group of genetically heterogeneous, lethal diseases is
characterized by severe mental retardation, loss of multi-
ple peroxisomal metabolic functions, and defective import
of one or more classes of peroxisomal matrix proteins. All
previously characterized PBD cell lines import PMPs nor-
mally and contain numerous peroxisomes, leading to the
hypothesis that the PBDs are caused by defects in peroxi-
somal matrix protein import and not the biogenesis of per-
oxisome membranes (Santos et al., 1988a). The cellular
and molecular analysis of PBD cells has demonstrated that
PMP import is fundamentally different from the matrix
protein import pathways, but until now has done little to
advance our understanding of peroxisome membrane bio-
genesis, or PMP import.
Here we describe a cell line from a Zellweger syndrome
patient, PBD061, that differs from previously reported
PBD cell lines. Specifically, it is unable to import PMPs,
and lacks detectable peroxisome membranes. The charac- 
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terization of PBD061 cells and the gene product defective
in this cell line, PEX16, revealed the following: PEX16 is
required for peroxisome synthesis, and peroxisomes can
form in the absence of preexisting peroxisomes. Possible
mechanisms for peroxisome synthesis in rescued PBD061
cells and in normal cells are discussed.
 
Materials and Methods
 
Tissue Culture, Cell Lines, and Antibodies
 
Skin fibroblasts from PBD patients were obtained from Ann and Hugo
Moser (The Kennedy Krieger Institute, Baltimore, MD), and from the
Coriell Cell Repository (Camden, NJ). All cell lines were cultured in high
glucose DME that was supplemented with penicillin, streptomycin, and
10% fetal calf serum. Cell lines in this report are referred to by a unique
PBD number with the exception of the normal human fibroblast cell line,
5756T (an SV-40Ðtransformed derivative of GM5756; Coriell Cell Reposi-
tory), and the hepatoblastoma cell line HepG2 (a gift from Michael
Schrader, Baltimore, MD). The CG1 cell line, PBD009, has inactivating
mutations on both 
 
PEX1
 
 alleles, and lacks detectable levels of 
 
PEX1
 
mRNA and protein (Reuber et al., 1997). The CG2 cell line, PBD005, is
homozygous for an inactivating mutation in 
 
PEX5
 
, and lacks detectable
levels of 
 
PEX5
 
 mRNA and protein (Dodt et al., 1995). The CG3 cell line,
PBD097, is a compound heterozygote for two inactivating frameshift mu-
tations in 
 
PEX12
 
 (Chang et al., 1997). The CG4 cell line, PBD105, is also
a compound heterozygote for two inactivating frameshift mutations, ex-
cept in the 
 
PEX6
 
 gene (Yahraus et al., 1996). The CG7 cell line, PBD100,
is homozygous for a splice donor site mutation in 
 
PEX10
 
 and expresses a
 
PEX10
 
 mRNA with a large internal deletion that lacks 
 
PEX10
 
 activity
(Warren et al., 1998). The gene that is mutated in cells from complemen-
tation group 8 of the PBDs is unknown but the CG8 cell line used in this
study, PBD109, was equally or more severely deficient in peroxisomal ma-
trix protein import than any other CG8 cell line. The CG9 cell line,
PBD061, is equivalent to GM6231, a Zellweger syndrome cell line from
the Coriell Cell Repository. The CG10 cell line, PBD094, is homozygous
for an inactivating nonsense mutation in the 
 
PEX2
 
 gene (Shimozawa et al.,
1992). The CG13 cell line, PBD222, is the sole representative of this com-
plementation group and was derived from a neonatal adrenoleukodystro-
phy patient. Again, the gene defective in this patient remains to be deter-
mined. Aside from PBD222, all cell lines used in this study were derived
from severely affected Zellweger syndrome patients.
Antibodies to PMP70 were obtained from Gerardo Jimenez-Sanchez
and David Valle (The Johns Hopkins University School of Medicine, Bal-
timore, MD). Antibodies to P70R were obtained from Wilhelm Just (Uni-
versity of Heidelberg, Heidelberg, Germany). mAbs to the myc epitope
tag were obtained from the tissue culture supernatant of the hybridoma
1-9E10 (Evan et al., 1985). To generate antibodies to PEX16, we first ex-
pressed amino acids 145Ð336 of 
 
PEX16
 
 in fusion with the maltose binding
protein. The resulting maltose binding proteinÐ
 
PEX16
 
 fusion was purified
by affinity chromatography on an amylose resin according to the manufac-
turerÕs instructions (New England Biolabs Inc.). The purified fusion pro-
tein was then injected into rabbits and polyclonal sera were collected. The
sera displaying the highest titer against in vitro synthesized PEX16 was
used for all experiments. Fluorescently labeled secondary antibodies were
obtained from commercial sources. Horseradish peroxidaseÐlabeled antiÐ
rabbit secondary antibodies were also obtained from commercial sources.
 
Immunofluorescence
 
Cells were cultured on glass coverslips and processed for indirect immu-
nofluorescence as follows. Cells were washed twice in DulbeccoÕs phos-
phate buffered saline (DPBS; 0.2 g/liter KCl, 0.2 g/liter KH
 
2
 
PO
 
4
 
, 8.0 g/liter
NaCl, 21.6 g/liter Ha
 
2
 
HPO
 
4
 
, pH 7.1), and fixed for 15 min in 3.7% formal-
dehyde in DPBS, followed by two washes with DPBS. Unless otherwise
noted, the cells were then permeabilized by incubation in 1% Triton X-100
in DPBS for 5 min to permeabilize all cellular membranes. Cells were
washed twice in DPBS, and incubated with the primary antibody or anti-
bodies for 15 min. All antibody incubations were performed in DPBS that
was supplemented with 5% nonspecific goat serum. Next, the cells were
washed 10 times with DPBS, and incubated with the appropriate second-
ary antibodies in 5% nonspecific goat serum and DPBS for 15 min. Cells
were washed 10 times, and mounted on glass slides in a solution of 100 mM
 
Tris-HCl, pH 8.5, 90% glycerol, and 0.1% 
 
para
 
-phenylenediamine. For
differential permeabilization experiments in which the plasma membrane
is permeabilized but the peroxisome membrane remains intact, the Triton
X-100 incubation was omitted and cells were permeabilized instead by in-
cubation in 25 
 
m
 
g/ml digitonin in DPBS for 5 min. Cells were visualized on
an Olympus fluorescence microscope and all images were collected on
film (T-Maxx 400; Eastman-Kodak).
 
PEX16 Cloning, Mutation Detection, and Plasmids
 
Candidate cDNAs for the mammalian 
 
PEX16
 
 gene were identified by
searching the database of expressed sequence tags using the TBLASTN
algorithm. A mouse cDNA capable of encoding a protein similar to 
 
Yar-
rowia lipolytica
 
 PEX16 was identified. The sequence of the murine
 
PEX16
 
 cDNA was used to identify a human 
 
PEX16
 
 cDNA by BLAST
searches of the human database of expressed sequence tags. Clones en-
coding the human 
 
PEX16
 
 cDNA were obtained from Genome Systems
Inc. and sequenced in their entirety. The 
 
PEX16
 
 ORF was also amplified
from a full-length cDNA clone using 
 
PEX16
 
-specific oligonucleotides
5
 
9
 
-CCCGGTACCATGGAGAAGCTGCGGCTCCTGGGC-3
 
9
 
 and 5
 
9
 
-CCA-
AGCGGCCGCAGTTTTATTAGGGAAGAGGGGC-3
 
9
 
. The resulting
PCR products were digested with Asp718 and NotI, and cloned between
the Asp718 and NotI sites of pcDNA3, creating pcDNA3-
 
PEX16.
 
 The
 
PEX16
 
 insert in this plasmid was sequenced in its entirety to ensure that
no mutations were introduced during the cloning process. The cDNA and
deduced protein sequences for human 
 
PEX16
 
 are available from Gen-
Bank (accession number AF118240).
Mutation detection was performed initially by RT-PCR. RNA was ex-
tracted from PBD061 cells and from a control human fibroblast and con-
verted to 
 
PEX16
 
 cDNA as follows. Approximately 1 
 
m
 
g of total RNA
from an unaffected individual and from PBD061 was used as template in a
cDNA synthesis reaction using a 
 
PEX16
 
-specific oligonucleotide (5
 
9
 
-CCA-
AGCGGCCGCAGTTTTATTAGGGAAGAGGGGC-3
 
9
 
) and Superscript
reverse transcriptase (Life Sciences Inc.). 3 
 
m
 
l of the cDNA synthesis reac-
tion products was used as template in PCR using the 
 
PEX16
 
-specific oligonu-
cleotides 5
 
9
 
-CCTAAGACCGGAAGCAGGAAGGAG-3
 
9
 
, and 5
 
9
 
-ACAC-
CCTCCTTCCGGGAGGTCTGT-3
 
9
 
 that lie in the 5
 
9
 
 and 3
 
9
 
 untranslated
regions of the 
 
PEX16
 
 cDNA. A product of the correct size was obtained
from each reaction. However, the yield of 
 
PEX16
 
 cDNA from PBD061
RNA was significantly lower than that obtained from control RNAs, a
result that was consistently observed in multiple experiments. The 
 
PEX16
 
cDNAs from the control group, and PBD061 cells were sequenced directly
and in their entirety. The control fragment matched the 
 
PEX16
 
 cDNA se-
quence exactly. In contrast, the 
 
PEX16
 
 cDNA from PBD061 had a 1-bp
substitution in which the first nucleotide of the arginine 176 codon, CGA,
was converted to a T, terminating the 
 
PEX16
 
 ORF about halfway through
the coding region (data not shown).
The sequence chromatograph of the 
 
PEX16
 
 cDNA from PBD061
showed no evidence of the C at this position. However, a wide array of
mutations may result in altered mRNA abundance and it is, therefore, com-
mon for a mutation to appear homozygous at the cDNA level even though
there may be different mutations on the two alleles in the patient. To test
whether PBD061 cells were homozygous for the R176ter mutation we first
had to determine the 
 
PEX16
 
 genomic organization in the region of the
mutation. Oligonucleotide primers flanking the site of mutation, and
based on the cDNA sequence, were used in various combinations in PCR
reactions with total human genomic DNA from an unaffected individual
as a template. One set of oligonucleotides (5
 
9
 
-CAGCCCTGGCAAC-
CATGAGCAGTC-3
 
9
 
 and 5
 
9
 
-CAAAAACTCTGCGATGGTCTCC-3
 
9
 
)
amplified a DNA fragment that was 
 
z
 
100 bp larger than expected from
the cDNA sequence, indicating that it spanned an intron and therefore
would be derived from genomic DNA. Direct sequence analysis con-
firmed this hypothesis as the cDNA sequences of the amplicon were inter-
rupted by a 134-bp segment that had all of the features of a human intron.
These same oligonucleotides were used to amplify a 
 
PEX16
 
 gene frag-
ment spanning the site of mutation from the genomic DNA of an unaf-
fected individual and PBD061. The structure of each product was deter-
mined by direct sequence analysis.
The 
 
PEX16
 
 expression vector, pcDNA3-
 
PEX16
 
, was described above.
The plasmid pcDNA3-
 
PEX16
 
/R176ter was created by T/A cloning the
PEX16 RT-PCR product that was generated from PBD061 RNA into the
pCR2.1 vector (Invitrogen Corp.). The resulting clone was sequenced in
its entirety to ensure that no other mutations were introduced during the
amplification process. The 
 
PEX16
 
/R176ter cDNA was released from this
plasmid, pCR2.1-
 
PEX16
 
/R176ter, by digestion with EcoRI and cloned 
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into the unique EcoRI site of pcDNA3, creating pcDNA3-
 
PEX16
 
/
R176ter. The COOH-terminal myc-tagged derivative of the 
 
PEX16
 
cDNA was generated by PCR using the wild-type 
 
PEX16
 
 cDNA as a tem-
plate, the oligonucleotide 5
 
9
 
-CCCGGTACCATGGAGAAGCTGCGG-
CTCCTGGGC-3
 
9
 
 at the 5
 
9
 
 end and the oligonucleotide 5
 
9
 
-CCAAAG-
ATCTGCCCCAACTGTAGAAGTAGATTTTC-3
 
9
 
 at the 3
 
9
 
 end, which
replaces the stop codon with a BglII site. The resulting fragment was
cleaved with Asp718 and BglII and inserted between the Asp718 and
BamHI sites of pcDNA3-myc (Yahraus et al., 1996), creating the plasmid
pcDNA3-
 
PEX16myc.
 
 This plasmid carries a modified 
 
PEX16
 
 ORF that
encodes the 10Ðamino acid long c-myc epitope tag at the COOH terminus
of PEX16. The NH
 
2
 
-terminal myc-tagged derivative of the 
 
PEX16
 
 cDNA
was generated by PCR using the wild-type 
 
PEX16
 
 cDNA as a template, the
oligonucleotide 5
 
9
 
-CCCGTCGACGGAGAAGCTGCGGCTCCTGGG-
CCTC-3
 
9
 
 at the 5
 
9
 
 end and the oligonucleotide 5
 
9
 
-CCAAGCGGCCGC-
AGTTTTATTAGGGAAGAGGGGC-3
 
9
 
 at the 3
 
9
 
 end. This cDNA frag-
ment was cleaved with SalI and NotI, and cloned between the XhoI and
NotI sites of the NH
 
2
 
-terminal myc tag vector, pcDNA3-N-myc. This plas-
mid carries a high efficiency initiation codon, and the c-myc epitope tag
upstream of the XhoI and NotI sites. The resulting plasmid, pcDNA3-
 
mycPEX16
 
, encodes the 10Ðamino acid long c-myc epitope tag at the 5
 
9
 
 end
of the PEX16 ORF. The plasmid that expresses the maltose binding pro-
teinÐPEX16 fusion (pMBP-PEX16) was created by amplifying a subfrag-
ment of the 
 
PEX16
 
 cDNA by PCR using the 
 
PEX16
 
 cDNA as a template,
and the oligonucleotides 5
 
9
 
-CCCGTCGACACTGGACAGAGAGAC-
CCAGGCAC-3
 
9
 
, and 5
 
9
 
-CCAAGCGGCCGCAGTTTTATTAGGGAA-
GAGGGGC-3
 
9
 
. This fragment encoding amino acids 145Ð336 of PEX16,
was cleaved with SalI and NotI, and inserted between the SalI and NotI
sites of pMBP, a modified version of pMALc2 (New England Biolabs Inc.)
The plasmids designed to express PMP70myc, PEX12myc, PMP32myc,
PEX3myc, PEX11
 
a
 
myc, and PEX11
 
b
 
myc all consist of the full-length hu-
man cDNA cloned into the mammalian expression vector pcDNA3-myc
in such a way as to encode the 10Ðamino acid myc tag after the COOH-
terminal amino acid of each protein, followed immediately by a stop
codon.
 
Transfection and Microinjection
 
All cell lines were actively growing before transfection or injection. Trans-
fections were performed by growing cells to near confluency on two T75
flasks, harvesting the cells by trypsinization, and electroporating them as
described in Chang et al. (1997). Microinjections were performed with
DNA at a concentration of 1 
 
m
 
g/ml in reverse phosphate buffered saline
(4 mM NaHPO
 
4
 
, 1 mM KH
 
2
 
PO
 
4
 
, 140 mM KCl, pH 7.3). DNAs were in-
jected into the nucleus of cells at a pressure of 100 mmHg for 0.4 s.
 
Protein Preps, Fractionations, Protease Protection, and 
Western Blots
 
Total cellular proteins were extracted from cultured fibroblasts as described
(Dodt and Gould, 1996). For subcellular fractionation experiments, postnu-
clear supernatants were prepared from HepG2 cells by homogenization in a
Balch homogenizer followed by successive centrifugation steps to remove
nuclei and unbroken cells. The resulting clarified supernatant was sepa-
rated by density gradient centrifugation (Nycodenz; Nycomed Pharma) as
described in Dodt et al. (1995). Equal amounts of each fraction were as-
sayed for catalase, succinate dehydrogenase (SDH), and NADPH-cyto-
chrome reductase (NCR) to follow the peroxisomes, mitochondria, and
microsomes, respectively. Equal amounts of each fraction were also sepa-
rated by SDS-PAGE and assayed for PEX16 levels by Western blot as de-
scribed in Crane et al. (1994).
For membrane extractions, a light mitochondrial pellet was obtained by
centrifugation of a HepG2 postnuclear supernatant at 25,000 
 
g
 
 for 30 min.
The pellet fraction was then extracted with 10 mM Tris, pH 8.3 on ice for
20 min with agitation. This sample was separated into a membrane pellet,
and a soluble supernatant by centrifugation at 200,000 
 
g
 
 for 30 min. The
supernatant was saved and the pellet was subjected to extraction with 1 M
NaCl on ice for 20 min with agitation. This sample was separated into a
membrane pellet, and a soluble supernatant by centrifugation at 200,000 
 
g
 
for 30 min. The supernatant was saved, and the pellet was subjected to ex-
traction with 100 mM Na
 
2
 
CO
 
3
 
 pH 11.5 on ice for 20 min with agitation.
The carbonate extracted supernatant and pellet were separated by cen-
trifugation at 200,000 
 
g
 
 for 30 min. The levels of PEX16 in each sample
were determined by semiquantitative Western blotting after separating
equal proportions of the three supernatants and the carbonate extracted
pellet by SDS-PAGE.
Protease protection experiments were performed as follows. A postnu-
clear supernatant was prepared from HepG2 cells and a light mitochon-
drial pellet was obtained as above. This was resuspended in 0.25 M su-
crose, 10 mM Tris-HCl, pH 8.0, and 1 mM EDTA. Equal proportions
were aliquoted to eight different tubes. Triton X-100 was added to four of
the tubes to a final concentration of 1%. Either 0, 15, 30, or 60 
 
m
 
g of the
protease trypsin (Sigma Chemical Co.) was added to an aliquot that con-
tained Triton X-100 and to an aliquot that lacked protease. These samples
were incubated on ice for 20 min, and protease digestion was terminated
by adding a twofold excess of bovine trypsin inhibitor. Equal proportions
of each sample were separated by SDS-PAGE and PEX16 was detected
by Western blot.
 
Results
 
PBD061 Cells Are Defective in PMP Import
 
Little is known about the mechanisms of PMP import or
the synthesis of peroxisome membranes. To identify cell
lines that are defective in these processes we screened skin
fibroblasts from over 100 PBD patients for the presence of
PMP-containing peroxisomal structures. Each cell line was
processed for indirect immunofluorescence using antibod-
ies specific for PMP70, an integral membrane protein of
the peroxisome. Previous studies have reported that PBD
cells contain peroxisomes and import PMPs (Santos et al.,
1988a, 1988b) and we detected numerous PMP70-contain-
ing peroxisomes in virtually all cell lines examined. These
included representatives of complementation groups 1, 2,
3, 4, 7, 8, 10, and 13 (Fig. 1). However, we did identify one
cell line, PBD061, which failed to import PMP70 into per-
oxisomes (Fig. 1, I). This cell line was derived from a se-
verely affected Zellweger syndrome patient and is the sole
representative of PBD complementation group 9 (Moser
et al., 1995). To test whether the absence of PMP70 staining
in PBD061 cells reflected a generalized defect in PMP im-
port or a peculiarity of PMP70 distribution, representatives
of all complementation groups were also processed for indi-
rect immunofluorescence using antibodies specific for other
PMPs, including ALDP (Mosser et al., 1994), and P70R
(Shani et al., 1997). These antibodies also revealed the pres-
ence of numerous PMP-containing peroxisomes in repre-
sentatives of all complementation groups except for the
CG9 cell line, PBD061 (data not shown).
As an independent test of this phenotype we followed the
distribution of overexpressed PMPs in this cell line. Plas-
mids designed to express the integral peroxisomal mem-
brane proteins PMP70myc, PEX12myc and PMP32myc (a
human peroxisomal solute carrier) were transfected into
PBD061 cells and a control PBD fibroblast line, PBD094,
which is mutated in the 
 
PEX2
 
 gene (Shimozawa et al.,
1992). We were unable to detect peroxisomal or vesicular
staining for these PMPs in PBD061 cells, even though all
three proteins were efficiently targeted to peroxisome
membranes in PBD094 cells (Fig. 2). Similar rates of trans-
fection in both cell lines were confirmed by cotransfection
with a cytosolic marker expression vector (data not shown).
Similar results were observed in cells transfected with ex-
pression vectors designed to express other human PMPs,
including PEX3myc (Kammerer et al., 1998), PEX10myc
(Warren et al., 1998), PEX11
 
a
 
myc (Schrader et al., 1998),
PEX11
 
b
 
myc (Schrader et al., 1998), and PEX13myc (Gould 
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et al., 1996) (data not shown). Although we were unable to
detect peroxisomal or vesicular structures with any of the
11 PMPs tested, it is possible that some as yet unidentified
PMPs may reside in some type of peroxisome-related
structure in PBD061 cells.
To better understand the fates of PMPs in PBD061 cells,
total cellular protein was extracted from the CG9 cell line,
PBD061, and a CG10 cell line, PBD094, as well as from
PBD061, and PBD094 cells that had been transfected with
the PEX12myc expression vector. The abundance of the
PMPs (PMP70, P70R, PEX14, and PEX12myc) were then
determined by immunoblot with antibodies specific for
each protein (Fig. 3). As evident from this experiment, lev-
els of full-length PMP70 and P70R in PBD061 cells were
below the limit of detection in PBD061 cells but were
readily detected in PBD094 cells, indicating that these pro-
teins might be degraded in PBD061 cells. This hypothesis
is supported by the presence of antiÐP70R-reactive prod-
ucts of lower molecular mass in PBD061 cells, but not in
PBD094 cells. However, this was not the fate of all PMPs,
since levels of PEX14 were similar in PBD061 cells and
PBD094 cells, as were levels of PEX12myc. Thus, the fate
of PMPs in a cell line defective in PMP import varies from
protein to protein, just as the fate of peroxisomal matrix
proteins varies in cells with specific defects in matrix pro-
tein import (Lazarow and Fujiki, 1985; Santos et al., 1988a,
1988b).
 
Identification of PEX16, the Gene Mutated in
CG9 Cells
 
The prevailing model of peroxisome biogenesis holds that
peroxisomes are formed by division of preexisting peroxi-
somes. Thus, it was an open question as to whether peroxi-
some synthesis could be restored in a cell line such as
PBD061; and the identification of the gene defective in
PBD061 cells would likely have a significant impact on our
understanding of peroxisome biogenesis. We employed
the homology probing strategy that has been used previ-
ously to identify human homologues of other yeast 
 
PEX
 
genes (Dodt et al., 1996). The database of expressed se-
quence tags was searched for mammalian homologues of
the 
 
Y. lipolytica PEX16
 
 gene and a single human homo-
logue was identified (Fig. 4 A). This human 
 
PEX16
 
 cDNA
Figure 1. The CG9 cell line lacks detectable peroxisomes. Human fibroblasts from representatives of nine different complementation
groups of the PBDs were processed for indirect immunofluorescence using rabbit antibodies specific for PMP70, and Texas redÐlabeled
goat antiÐrabbit IgG secondary antibodies. Numerous peroxisomal structures were detected in (A) the PEX1-deficient CG1 cell line,
PBD009; (B) the PEX5-deficient CG2 cell line, PBD005; (C) the PEX12-deficient CG3 cell line, PBD097; (D) the PEX6-deficient CG4
cell line, PBD105; (E) the PEX10-deficient CG7 cell line, PBD100; (F) the CG8 cell line, PBD109; (G) the PEX2-deficient CG10 cell line,
PBD094; and (H) the CG13 cell line, PBD222. In contrast, (I) the CG9 cell line, PBD061, lacks detectable peroxisomes. Bar, 10 mm. 
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was inserted into a mammalian expression vector and the
resulting plasmid, pcDNA3-PEX16, was transfected into
PBD061 cells. 3 d after transfection the cells were pro-
cessed for indirect immunofluorescence using antibodies
specific for the peroxisome membrane marker, PMP70,
and a peroxisomal matrix protein, catalase. Expression of
PEX16 rescued both PMP and matrix protein import in
PBD061 cells, demonstrating that peroxisomes can form in
the absence of preexisting peroxisomes (Fig. 4). No rescue
was observed in cells transfected with the vector alone.
The functional complementation experiments described
above indicated that this patient would have mutations in
the PEX16 gene. The PEX16 cDNA was amplified from
control and PBD061 RNAs by RT-PCR, and direct se-
quence analysis revealed the presence of a nonsense muta-
tion in the PEX16/PBD061 cDNA population (data not
shown). This mutation, a C-to-T transition at a CpG dinu-
cleotide, converts the arginine 176 codon to a nonsense
codon (R176ter), and appeared to represent the only form
of PEX16 mRNA present in PBD061 cells. To determine
whether this mutation was present at the genomic DNA
level we amplified an appropriate fragment of the PEX16
gene from control and PBD061 genomic DNAs. Direct se-
quence analysis showed only the mutant form of the gene
in PBD061 (Fig. 5, A and B), indicating that this patient is
homozygous for the R176ter mutation.
The R176ter mutation is predicted to delete the COOH-
terminal half of PEX16, suggesting that it may have a severe
effect on gene function. To test this directly we engineered
the R176ter mutation into the PEX16 cDNA expression
vector and assayed the effects of this mutation by functional
complementation. PBD061 fibroblasts were transfected
with the expression vectors pcDNA3-HsPEX16/R176ter
and pcDNA3-HsPEX16. After 3 d, cells from each popula-
tion were processed for indirect immunofluorescence using
anti-PMP70 and anticatalase antibodies to assess the recon-
Figure 3. Different fates for differ-
ent PMPs in PBD061 cells. Total
cellular protein was extracted from
the CG9 cell line, PBD061, and the
CG10 cell line, PBD094. Equal
amounts of each lysate (by protein)
were separated by SDS-PAGE, and
blotted with antibodies specific for
the PMPs PMP70 (A), P70R (B);
and PEX14 (C). In addition, total
cellular protein was extracted from
PBD061 and PBD094 cells that had
been transfected with the PEX12myc
expression vector. Equal amounts
of each lysate (by protein) were
separated by SDS-PAGE, and blot-
ted with antibodies specific for the
myc epotope tag (D).
Figure 2. The PMP import defect of CG9 cells applies to numerous PMPs. The CG9 cell line, PBD061 (AÐC); and the CG10 cell line,
PBD094 (DÐF), were transfected with vectors designed to express PMP70 myc (A and D), PEX12myc (B and E), and PMP32myc (C
and F). 2 d after transfection the cells were processed for indirect immunofluorescence using antibodies specific for the myc tag. The
peroxisomal nature of the punctate structures in PBD094 cells was confirmed by double label experiments with peroxisomal membrane
markers (data not shown). Bar, 10 mm.The Journal of Cell Biology, Volume 144, 1999 260
stitution of peroxisome biogenesis. The PEX16/R176ter cDNA
displayed no rescue activity, indicating that the R176ter mu-
tation had a severe effect on PEX16 function (Fig. 5, CÐF).
PEX16 Encodes an Integral PMP with Its Termini 
Extending into the Cytoplasm
While the above results demonstrated that PEX16 is re-
quired for peroxisome biogenesis they did not reveal how
PEX16 might perform this role. Since the physical location
of proteins can provide useful insight into their function
we first determined the subcellular distribution of PEX16.
Antibodies to PEX16 were generated and recognized a
polypeptide of 38 kD, the predicted molecular mass of
PEX16, in human cell extracts (data not shown). These an-
tibodies were used to localize PEX16 in subcellular frac-
tionation experiments. A postnuclear supernatant was
prepared from HepG2 cells and fractionated by Nycodenz
density gradient centrifugation. Fractions were assayed for
marker enzymes of peroxisomes, mitochondria, and mi-
crosomes, as well as PEX16 (Fig. 6 A). PEX16 behaved as
a typical PMP, localizing only to the high-density, catalase-
containing peroxisomal fractions (rupture of peroxisomes
during homogenization and centrifugation leads to the
presence of peroxisomal matrix proteins at the top of the
gradient, demonstrated here by the presence of catalase
activity in the low density fractions).
Sequence analysis predicted that the 336Ðamino acid-long
PEX16 protein contained two transmembrane domains:
one among amino acids 110Ð144, and another spanning
amino acids 222Ð243 (Fig. 3 A). To test the hypothesis that
PEX16 was a PMP we prepared another postnuclear super-
natant from HepG2 cells and collected peroxisomes, mito-
Figure 5. PBD061 cells have an inactivating mutation in PEX16.
Direct sequence analysis of a PEX16 fragment from (A) PBD061
and (B) an unaffected individual showing the CGA to TGA non-
sense mutation in PBD061 genomic DNA. The homogeneous na-
ture of the PBD061 sequence indicates that this patient is ho-
mozygous for the R176ter mutation. The effect of this mutation
was assayed by transfecting PBD061 cells with pcDNA3-PEX16/
R176ter (C and D) a plasmid designed to express the mutated
form of the cDNA; and pcDNA3-PEX16 (E and F). 2 d after
transfection the cells were processed for indirect immunofluores-
cence using rabbit antibodies specific for PMP70 (C and E) and
sheep antibodies specific for catalase (D and F), followed by fluo-
rescein-labeled goat antiÐrabbit and Texas redÐlabeled goat antiÐ
sheep secondary antibodies. Bar, 10 mm.
Figure 4. PEX16 expression restores peroxisome synthesis in the
CG9 cell line, PBD061. (A) The deduced amino acid sequence of
human PEX16. Amino acid positions are noted on the left and
the two predicted transmembrane domains are underlined.
PBD061 cells were transfected with the plasmids pcDNA3 (B
and D), and pcDNA3-PEX16 (C and E). 3 d later the cells were
processed for indirect immunofluorescence using rabbit antibod-
ies specific for PMP70 (B and C), and sheep antibodies specific
for catalase (D and E), followed by fluorescein-labeled goat antiÐ
rabbit and Texas redÐlabeled goat antiÐsheep secondary antibod-
ies. Note the colocalization of PMP70 and catalase in the rescued
cell (C and E). Bar, 10 mm.South and Gould PEX16 and Peroxisome Membrane Synthesis 261
chondria, and other large organelles by centrifugation at
25,000 g. This light mitochondrial fraction was subjected to
successive extractions with hypotonic buffer (10 mM Tris,
pH 8.5), high salt (1 M NaCl), and high pH (100 mM
Na2CO3, pH 11.5). These treatments are designed to release
soluble peroxisomal enzymes, electrostatically associated
membrane proteins, and tightly associated membrane pro-
teins, respectively (Fujiki et al., 1982). Integral PMPs are
predicted to remain in the carbonate-extracted membrane
pellet. Western blot analysis revealed that PEX16 behaved
as an integral PMP, remaining in the membrane pellet even
after carbonate extraction (Fig. 6 B).
To assess the topology of PEX16 in the peroxisome
membrane we first performed protease protection experi-
ments on a light mitochondrial fraction of HepG2 cells.
Exogenous protease reduced PEX16 from 38 to 15 kD in
the absence of detergent (Fig. 6 C), demonstrating that a
significant portion of PEX16 extends into the cytoplasm.
The anti-PEX16 antibodies used in this experiment were
raised against its COOH-terminal 189 amino acids, which
comprises the segment between the two transmembrane
domains, the second transmembrane domain, and the 10-kD
COOH-terminal tail. The only topology that is consistent
with these results is for PEX16 to reside in the peroxisome
membrane with its NH2 and COOH termini extending
into the cytoplasm and its intermembrane loop protected
in the peroxisome lumen.
To test PEX16 orientation by an independent method we
generated tagged versions of the PEX16 cDNA expression
vectors: one designed to express the c-myc tag at the NH2
terminus of PEX16 (pcDNA3-mycPEX16), and one de-
signed to express the c-myc tag at its COOH terminus
(pcDNA3-PEX16myc). Normal human fibroblasts were
transfected with these plasmids. After 2 d of incubation, the
cells were processed for immunofluorescence using anti-
bodies specific for the myc epitope tag and for catalase, a
peroxisomal matrix protein (Fig. 7). The mycPEX16 and
PEX16myc proteins both colocalized with catalase, con-
firming that PEX16 is a peroxisomal protein. Furthermore,
the mycPEX16 and PEX16myc proteins were detected un-
Figure 7. The NH2 and COOH termini of PEX16 are exposed to
the cytoplasm. Normal human fibroblasts were transfected with
pcDNA3-mycPEX16 (AÐD) or pcDNA3-PEX16myc (EÐH). 2 d
after transfection cells were fixed and processed for indirect
immunofluorescence under standard permeabilization conditions
(A, B, E, and F) or under differential permeabilization condi-
tions (C, D, G, and H). Cells were labeled with mouse mAbs spe-
cific for the myc epitope tag (A, C, E, and G) and with sheep an-
tibodies  specific for catalase (B, D, F, and H), followed by
Texas redÐlabeled goat antiÐmouse and fluorescein-labeled goat
antiÐsheep secondary antibodies. Bar, 10 mm.
Figure 6. PEX16 encodes an integral peroxisomal membrane
protein. (A) A postnuclear supernatant of HepG2 cells was frac-
tionated by density gradient centrifugation. Equal proportions of
each fraction were assayed for the marker enzymes catalase, a
peroxisomal enzyme, SDH, a mitochondrial marker, and NCR,
an ER-associated enzyme. Equal proportions of each fraction
were also assayed for levels of PEX16 by immunoblot (bottom).
These antibodies also detect an unknown protein of slightly
higher mobility in fraction 10. (B) PEX16 is present in high pH
carbonate-washed membranes. A light mitochondrial fraction
from HepG2 cells was separated into a hypotonic extraction su-
pernatant (lane 1); a high salt extraction supernatant (lane 2); a
high pH carbonate supernatant (lane 3); and a pellet of carbon-
ate-washed membranes (lane 4). Equal proportions of each frac-
tion were separated by SDS-PAGE and assayed for levels of
PEX16 by Western blot. (C) Protease protection experiments in-
dicate that PEX16 spans the membrane twice with its NH2 and
COOH termini exposed to the cytoplasm. A light mitochondrial
fraction was prepared from HepG2 cells and incubated with no
trypsin (lane 1), 15 mg trypsin (lane 2), 30 mg trypsin (lane 3), and
60 mg trypsin (lane 4). PEX16 is reduced to a protease-resistant
form of 15 kD, the size of the two transmembrane domains and
the intermembrane loop. Digestion in the presence of detergent
(1% Triton X-100) did not yield the 15-kD species (data not
shown).The Journal of Cell Biology, Volume 144, 1999 262
der differential permeabilization conditions that preclude
the detection of intraperoxisomal antigens, confirming that
PEX16 is a peroxisomal membrane protein with its NH2
and COOH termini extending into the cytoplasm. Surpris-
ingly, overexpression of mycPEX16 or PEX16myc never in-
duced peroxisome proliferation, suggesting that there may
be a functional distinction between factors that are required
for peroxisome membrane synthesis and those that are in-
volved in peroxisome proliferation, such as PEX11a and
PEX11b (Schrader et al., 1998). In control experiments, the
mycPEX16 and PEX16myc expression vectors were able to
rescue peroxisome synthesis in PBD061 cells, confirming
that these localization studies were performed with func-
tional forms of PEX16 (data not shown).
Biogenesis of PEX16
PEX16 was first identified in the yeast Y. lipolytica. Al-
though previous studies of PMP biogenesis have reported
that they are synthesized in the cytoplasm and imported
into peroxisomes posttranslationally (Lazarow and Fujiki,
1985), the analysis of Y. lipolytica PEX16 suggested that
this protein is inserted into the ER, and it traffics to perox-
isomes in a PEX1- and PEX6-dependent manner (Eitzen
et al., 1997; Titorenko et al., 1997; Titorenko and Rachu-
binski, 1998b). This model for PEX16 biogenesis is built
on the following observations: YlPEX16 accumulates in
the ER in the absence of either the PEX1 or PEX6 genes;
a pulse of YlPEX16 expression can be detected first in the
ER and subsequently in the peroxisome; and YlPEX16 is
modified by N-linked glycosylation. Given that the loss of
human PEX16 results in the absence of peroxisomes from
the cell, a similar biogenic pathway for human PEX16
would implicate the ER as a possible source of newly syn-
thesized peroxisomes in rescued PBD061 cells.
We first examined the distribution of PEX16myc in cells
that lack PEX1. PBD009 cells have inactivating mutations
on both PEX1 alleles, lack PEX1 mRNA and protein (Reu-
ber et al., 1997), and would be expected to accumulate
PEX16myc in the ER. In contrast to the expected results,
we found that PEX16myc colocalized with the peroxiso-
mal membrane marker, P70R, in PEX1-deficient PBD009
cells (Fig. 8, A and B). Next, we replicated the pulsed ex-
pression experiments. However, because of the need to
detect PEX16myc at the very earliest time points during
its expression, we had to deliver the PEX16myc expression
vector by nuclear microinjection rather than electropora-
tion. The normal human fibroblast line 5756T was injected
with pcDNA3-PEX16myc and then processed for indirect
immunofluorescence at 0.5, 1, 2, and 3 h after injection.
The first time point that we detected PEX16myc expres-
sion was 2 h after injection, at which point all of the
PEX16myc appeared to colocalize with the peroxisomal
membrane marker, P70R (Fig. 8, C and D). Examination
of multiple cells at the 2- and 3-h time points showed a
similar peroxisomal distribution of PEX16myc. The fact that
human PEX16 lacks a consensus sequence for N-linked
oligosaccharide addition, Asn-Xaa-Ser/Thr, made it im-
possible to follow N-linked glycosylation as a test of
whether PEX16 entered the ER before its delivery to per-
oxisomes.
The recent evidence for ER involvement in peroxisome
biogenesis is not limited to the biogenesis of PEX16 in Y.
lipolytica. Other tantalizing evidence includes the observa-
tion that brefeldin A (BFA) blocks peroxisome biogenesis
in Hansenula polymorpha (Solomos et al., 1997), and the
finding that ARF and COPI may play a role in peroxisome
proliferation in mammalian cells (Passreiter et al., 1998).
Since PEX16 plays an essential role in peroxisome synthe-
sis we tested whether BFA might block the targeting of
PEX16 to peroxisomes in normal cells. Normal human fi-
broblasts were incubated in 10 mg/ml BFA for 30 min and
then injected with the pcDNA3-PEX16myc expression vec-
Figure 8. PEX16 is rapidly targeted to peroxisomes in a PEX1-
independent and BFA-independent manner. The PEX1-deficient
cell line, PBD009, was transfected with pcDNA3-PEX16myc (A
and B), and processed for indirect immunofluorescence 2 d later
using mouse mAbs specific for the myc epitope tag (A), and rab-
bit antibodies specific for PMP70 (B), followed by fluorescein-
labeled goat antiÐmouse and Texas redÐlabeled goat antiÐrabbit
secondary antibodies. The normal human fibroblast cell line,
5756T, was injected with pcDNA3-PEX16myc and processed for
indirect immunofluorescence 2 h later using mouse mAbs spe-
cific for the myc epitope tag (C) and rabbit antibodies specific for
P70R (D), followed by fluorescein-labeled goat antiÐmouse and
Texas redÐlabeled goat antiÐrabbit secondary antibodies. (E and
F) 5756T cells that had been pretreated for 30 min with 10 mg/ml
BFA were injected with pcDNA3-PEX16myc, incubated for 2 h
in 10 mg/ml BFA, and processed for immunofluorescence using
mouse mAbs specific for the myc epitope tag (E) and rabbit anti-
bodies specific for P70R (F), followed by fluorescein-labeled goat
antiÐmouse and Texas redÐlabeled goat antiÐrabbit secondary
antibodies. Bar, 10 mm.South and Gould PEX16 and Peroxisome Membrane Synthesis 263
tor. The cells were maintained in the same concentration of
BFA and processed for indirect immunofluorescence at
various times after injection. Peroxisomal PEX16myc was
detected in peroxisomes 2 h after injection, demonstrating
that BFA did not inhibit the targeting of PEX16myc to
peroxisomes (Fig. 8, E and F). We also tested whether in-
cubation at 158C, a treatment that blocks exit of proteins
from the ER/Golgi intermediate compartment (Saraste
and Kuismanen, 1984), had any effect on PEX16myc tar-
geting to peroxisomes. We failed to detect any significant
inhibition of PEX16myc targeting to peroxisomes in cells
incubated at 158C as compared to cells incubated at 378C
(data not shown).
These experiments failed to provide evidence for an ER
role in PEX16myc biogenesis. Most proteins which enter
the ER do so cotranslationally, and, thus, are never
present in the cytosolic fraction before association with a
sedimental organelle. We attempted to follow the biogen-
esis of PEX16 in pulseÐchase experiments but were unable
to incorporate enough radioactivity into newly synthesized
PEX16 to detect the protein after even a long (1 h) pulse
labeling period (data not shown). Therefore, we were un-
Figure 9. Rescue of peroxi-
some synthesis in PBD061
cells occurs in a multistep
process. PBD061 cells were
injected with pcDNA3-
PEX16 and processed for in-
direct immunofluorescence
3 h later using rabbit antibod-
ies specific for P70R (A); and
sheep antibodies specific for
catalase (B); followed by flu-
orescein-labeled goat antiÐ
rabbit and Texas redÐlabeled
goat antiÐsheep secondary
antibodies. Note that many
of the peroxisomes appeared
to be undergoing elongation,
the first step in PEX11b-
mediated peroxisome prolif-
eration (Schrader et al., 1998).
Cells processed for 22 h (C
and D) and 72 h (E and F) af-
ter introduction of pcDNA3-
PEX16 were also processed
for indirect immunofluores-
cence using rabbit antibod-
ies specific for P70R (C and
E) and sheep antibodies spe-
cific for catalase (D and F),
followed by fluorescein-labeled
goat antiÐrabbit and Texas
redÐlabeled goat antiÐsheep
secondary antibodies. (G and
H) PBD061 cells were prein-
cubated for 30 min with 10
mg/ml BFA, injected with
pcDNA3-PEX16, and incu-
bated in 10 mg/ml BFA for
30 h. These cells were pro-
cessed for immunofluores-
cence using rabbit antibodies
specific for P70R (G); and
sheep antibodies specific for
catalase (H); followed by flu-
orescein-labeled goat antiÐ
rabbit and Texas redÐlabeled
goat antiÐsheep secondary
antibodies. Bar, 10 mm.The Journal of Cell Biology, Volume 144, 1999 264
able to use pulseÐchase experiments to determine whether
PEX16 enters the peroxisome directly from the cytoplasm
or indirectly through the ER.
Peroxisome Synthesis in Rescued CG9 Cells
The restoration of peroxisome synthesis in PBD061 cells
demonstrated that peroxisomes do not necessarily arise by
division of preexisting peroxisomes. To characterize the
process by which this occurs we followed the appearance of
peroxisomes at various times after injection of PBD061 cells
with the PEX16 expression vector. At each time point, cells
were processed for indirect immunofluorescence using anti-
bodies specific for the peroxisomal membrane marker,
PMP70, and the peroxisomal matrix marker, catalase. We
were unable to detect any peroxisomal structures 30 min, 1,
or 2 h after injection. However, by 3 h after injection we
started to observe P70R-containing structures that could be
detected over and above background staining (Fig. 9, A and
B). These structures generally did not contain the matrix
protein catalase, and were much reduced in number as com-
pared to normal cells or fully rescued PBD061 cells. In addi-
tion, peroxisomes detected at early time points often ap-
peared to form elongated structures similar to those that
form at early times in the PEX11b-mediated proliferation
of human peroxisomes.
At later time points, z18Ð24 h after injection or transfec-
tion, peroxisomes of more normal distribution and abun-
dance could be detected, although these commonly lacked
significant levels of catalase (Fig. 9, C and D). At later time
points (36Ð72 h after injection or transfection), the propor-
tion of rescued cells that contained both P70R and catalase
increased (Fig. 9, E and F), although it never attained unity.
In no instance did we observe punctate catalase in the ab-
sence of P70R-containing peroxisomes (data not shown).
Taken together, these results suggest that peroxisome syn-
thesis occurs in a multistep fashion beginning with the for-
mation of a limited number of PMP-containing vesicles, fol-
lowed by the elongation and proliferation of peroxisomal
structures, and ending with the robust import of peroxiso-
mal membrane and matrix proteins. However, it should be
noted that low but detectable numbers of catalase-import-
Figure 11. A model of peroxi-
some biogenesis in the absence
(top) and presence (bottom) of
preexisting peroxisomes. During
rescue of PBD061 cells, PEX16
creates nascent peroxisomes, pos-
sibly from a preperoxisomal vesi-
cle. These nascent PEX16-con-
taining peroxisomes then import
additional PMPs. The import of
PEX11 proteins allows these
structures to proliferate by fis-
sion or by budding, and the im-
port of other peroxins leads to
formation of a functional matrix
protein import apparatus. Un-
der normal conditions, peroxi-
somes would form primarily
from preexisting peroxisomes in
a PEX11-mediated process. Al-
though the targeting of PEX16 to
preperoxisomal structures may
be enhanced in the absence of
peroxisomal membranes, such a
process may also occur under
normal conditions.
Figure 10. Import of PEX16myc can precede P70R import in
peroxisomes of rescued PBD061 cells. PBD061 cells were in-
jected with pcDNA3-PEX16myc and processed for indirect im-
munofluorescence 3 h later using mouse mAbs specific for the
myc epitope tag (A and C) and rabbit antibodies specific for
P70R (B and D), followed by fluorescein-labeled goat antiÐ
mouse and Texas redÐlabeled goat antiÐsheep secondary anti-
bodies. Bar, 10 mm.South and Gould PEX16 and Peroxisome Membrane Synthesis 265
ing cells could be detected at early time points after injec-
tion of the PEX16 expression vector. Similar rates of rescue
were observed in the presence of BFA, demonstrating that
peroxisome synthesis is insensitive to this inhibitor of vesic-
ular transport (Fig. 9, G and H).
We repeated these kinetic studies using the PEX16myc
expression vector. PBD061 cells were injected with pcDNA3-
PEX16myc and processed for indirect immunofluores-
cence using antibodies specific for the myc epitope tag and
for P70R. As with the wild-type expression vector, rescue
could not be detected until 3 h after injection. At this time
point, some cells contained punctate structures that con-
tained both PEX16myc and P70R, but a few cells were ob-
served that contained only PEX16myc (Fig. 10).
Discussion
We have identified human PEX16, and established that an
inactivating mutation in this gene abolishes the synthesis
of peroxisomes in a Zellweger syndrome patient, PBD061.
These results expand the range of phenotypes and geno-
types that are associated with Zellweger syndrome, and
thus, expand our understanding of this lethal disease.
However, this study also enhances our understanding of
the molecular events involved in formation of peroxisome
membranes. Most importantly, the rescue of peroxisome
synthesis in PBD061 cells by PEX16 expression demon-
strates that preexisting peroxisomes, defined here as PMP-
containing vesicles, are not required for the formation of
new peroxisomes. While the elucidation of PEX16 func-
tion clearly requires additional studies our results do pro-
vide some insight into the biogenesis of peroxisome mem-
branes, at least in humans.
Perhaps the simplest model for peroxisome synthesis in
rescued PBD061 cells would be that PEX16 expression al-
lows the synthesis of peroxisomes from phospholipids and
PMPs rather than preexisting vesicles. However, this ap-
pears unlikely since there is no precedent for the synthesis
of biological membranes other than from a preexisting
lipid bilayer. An alternative hypothesis is that PEX16, ei-
ther alone or in conjunction with other proteins, converts a
preperoxisomal vesicle to recognizable peroxisomes by
mediating the import of other PMPs. This in turn would
lead to assembly of the matrix protein import apparatus,
and the subsequent import of peroxisomal matrix proteins,
completing the formation of mature peroxisomes.
Although this may explain the formation of peroxi-
somes during the rescue of PBD061 cells it is questionable
whether such a simple model can explain peroxisome syn-
thesis under all conditions. For instance, if peroxisomes
were typically formed by such a process we would expect
that the biogenesis of peroxisomes in PBD061 cells would
occur on roughly the same time course as the import of
PEX16 into peroxisomes of normal cells. However, this is
clearly not the case as PEX16 is imported into virtually all
peroxisomes of normal cells in ,2 h whereas the reconsti-
tution of normal peroxisomes in PBD061 cells requires
18Ð24 h. Furthermore, this model fails to incorporate roles
for the proliferation factors PEX11a and PEX11b (Schrader
et al., 1998) in the formation of peroxisomes.
These and other lines of evidence suggested instead that
peroxisome formation may occur by two distinct, yet over-
lapping pathways (Fig. 11). In this model, peroxisomes
would typically form by division of preexisting peroxi-
somes in a process mediated by PEX11a and PEX11b, not
PEX16. This would explain the hyperabundance of peroxi-
somes in cells overexpressing PEX11a or PEX11b, and
the fact that overexpression of PEX16 does not induce any
detectable proliferation of peroxisomes. In this model,
PEX16 would function normally in importing PMPs into
preexisting peroxisomes, and would itself be imported into
preexisting peroxisomes. In the absence of PEX16, PMP
import would cease, peroxisomes could not divide, and the
organelle would eventually be lost from the cell popula-
tion. In addition to this common route of peroxisome for-
mation we propose that PEX16 may, at low efficiency, be
targeted to an unknown preperoxisomal structure. The in-
corporation of PEX16 into such vesicles may convert them
to nascent peroxisomes that are able to import other
PMPs, and eventually to mature peroxisomes. This model
would not only explain the ability of PEX16 to rescue
PBD061 cells but would also explain: the presence of a
few, large peroxisomes in mutants lacking the PEX11 gene
(Erdmann and Blobel, 1995; Marshall et al., 1995); the per-
oxisome proliferation promoting activity of PEX11 pro-
teins; and the lack of peroxisome proliferation promoting
activity for PEX16.
This model is consistent with virtually all available data
on the formation of peroxisomes. However, it proposes
the existence of a structure that has yet to be identified,
the preperoxisome, and proposes an activity for PEX16
for which there is no direct evidence, PMP import. Never-
theless, this model serves as a useful starting point for con-
sidering how peroxisomes are formed. The preperoxiso-
mal structure need not be a dedicated structure awaiting
PEX16 for conversion into a nascent peroxisome, only a
subcellular vesicle that happens to incorporate a PEX16
molecule. As for the function of PEX16, our only evidence
that this protein is involved in PMP import is the inability
of PBD061 cells to import PMPs into peroxisomes, a phe-
notype that is also consistent with a defect in the synthesis
of the preperoxisomal structure of our model. Neverthe-
less, PEX16 has the appropriate structural requirements
for a role in PMP import. PEX16 is itself an integral PMP
and extends its NH2 and COOH termini into the cyto-
plasm where they may facilitate the recognition of PMPs
and/or their insertion into the peroxisome membrane. In
addition, PEX16 appears to be transported efficiently to
peroxisomes, and is detected only in peroxisomes, not
some other compartment, at steady state. It should be
noted that similar models have been proposed that impli-
cate the ER as the source of the preperoxisomal structure
(Kunau and Erdmann, 1998; Titorenko and Rachubinski,
1998a). However, our data do not provide evidence for a
role of the ER in peroxisome biogenesis.
In addition to improving our understanding of peroxi-
some synthesis and the molecular basis of Zellweger syn-
drome, this report also makes clear that homologues of the
same peroxisome biogenesis factor may have disparate
roles in different organisms. Although we identified human
PEX16 by its sequence similarity to Y. lipolytica PEX16,
there were significant differences between these proteins.
Prior reports have established that YlPEX16 is peripherally
associated with the inner face of the peroxisome membrane,The Journal of Cell Biology, Volume 144, 1999 266
and transported to peroxisomes via the ER in a PEX1- and
PEX6-dependent manner. Despite it playing a role in the im-
port of a subset of peroxisomal matrix proteins, YlPEX16 is
not required for synthesis of peroxisome membranes nor
PMP import (Eitzen et al., 1997; Titorenko et al., 1997;
Titorenko and Rachubinski, 1998b). In contrast, human
PEX16, an integral PMP with its NH2 and COOH termini
exposed to the cytoplasm, is required for PMP import and
peroxisome synthesis, and appears to traffic from the cyto-
plasm to the peroxisome in a PEX1-independent manner.
These differences emphasize the need for caution in extrap-
olating the functions of a particular peroxisome biogenesis
factor to its homologue in divergent species. Discretion in
this matter is emphasized further by the fact that the Sac-
charomyces cerevisiae genome lacks a PEX16 homologue,
even though the YlPEX16 and human PEX16 proteins
share 24% amino acid identity.
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